Advertisement
Screener

SPYRE THERAPEUTICS, INC. (SYRE) Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities

2.8 / 5 stars · 68/120 Roast Me

SPYRE THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities

SPYRE THERAPEUTICS, INC. (SYRE) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $225.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-04

  • SPYRE THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$3.43M.
  • SPYRE THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $3.65M.
  • SPYRE THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $3.12M, a 78.99% decline year-over-year.
  • SPYRE THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $4.41M, a 40.12% decline year-over-year.
  • SPYRE THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$764.00K, a 105.23% decline from fiscal 2024.
  • SPYRE THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $14.61M.
  • SPYRE THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$4.89M.
  • SPYRE THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$843.00K.
Period endIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 monthIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 monthIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filedIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 monthIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month
2026-06-30-$3.43M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$225.00K
10-Q · filed 2026-08-04
$3.35M
derived: sum of 3 quarters · filed 2026-08-04
$7.76M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$3.65M
10-Q · filed 2026-05-05
$6.78M
derived: sum of 2 quarters · filed 2026-05-05
$11.19M
derived: sum of 3 quarters · filed 2026-05-05
$8.89M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$3.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$7.54M
derived: sum of 2 quarters · filed 2026-02-19
$5.23M
derived: sum of 3 quarters · filed 2026-08-04
-$764.00K
10-K · filed 2026-02-19
2025-09-30$4.41M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$2.11M
derived: sum of 2 quarters · filed 2026-08-04
-$3.89M
10-Q · filed 2025-11-04
$10.98M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30-$2.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
-$8.30M
10-Q · filed 2026-08-04
$6.57M
derived: sum of 3 quarters · filed 2026-08-04
$13.93M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31-$6.00M
10-Q · filed 2026-05-05
$8.87M
derived: sum of 2 quarters · filed 2026-05-05
$16.23M
derived: sum of 3 quarters · filed 2026-05-05
$460.00K
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$14.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$22.23M
derived: sum of 2 quarters · filed 2026-02-19
$6.46M
derived: sum of 3 quarters · filed 2026-02-19
$14.61M
10-K · filed 2026-02-19
2024-09-30$7.37M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$8.41M
derived: sum of 2 quarters · filed 2025-11-04
-$257.00K
10-Q · filed 2025-11-04
-$1.15M
derived: sum of 4 quarters · filed 2026-02-19
2024-06-30-$15.77M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
-$7.62M
10-Q · filed 2025-08-05
-$8.51M
derived: sum of 3 quarters · filed 2026-02-19
-$11.46M
derived: sum of 4 quarters · filed 2026-02-19
2024-03-31$8.15M
10-Q · filed 2025-05-08
$7.26M
derived: sum of 2 quarters · filed 2026-02-19
$4.32M
derived: sum of 3 quarters · filed 2026-02-19
$6.42M
derived: sum of 4 quarters · filed 2026-02-19
2023-12-31-$891.00K
derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19
-$3.83M
derived: sum of 2 quarters · filed 2026-02-19
-$1.73M
derived: sum of 3 quarters · filed 2026-02-19
-$4.89M
10-K · filed 2026-02-19
2023-09-30-$2.94M
derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18
-$836.00K
derived: sum of 2 quarters · filed 2024-11-18
-$4.00M
10-Q/A · filed 2024-11-18
-$3.55M
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30$2.11M
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18
-$1.06M
10-Q/A · filed 2024-11-18
$189.00K
10-Q · filed 2023-08-11
-$608.00K
derived: sum of 3 quarters · filed 2025-02-27
-$1.02M
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31-$3.16M
10-Q/A · filed 2024-11-18
-$2.71M
derived: sum of 2 quarters · filed 2025-02-27
-$3.13M
derived: sum of 3 quarters · filed 2025-02-27
-$869.00K
derived: sum of 4 quarters · filed 2025-02-27
2022-12-31$450.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
$34.00K
derived: sum of 2 quarters · filed 2025-02-27
$2.29M
derived: sum of 3 quarters · filed 2025-02-27
-$843.00K
10-K · filed 2025-02-27
2022-09-30-$416.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$1.84M
derived: sum of 2 quarters · filed 2023-11-09
-$1.29M
10-Q · filed 2023-11-09
-$838.00K
derived: sum of 4 quarters · filed 2024-11-18
2022-06-30$2.26M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11
-$877.00K
10-Q · filed 2023-08-11
-$422.00K
derived: sum of 3 quarters · filed 2024-11-18
$617.00K
derived: sum of 4 quarters · filed 2024-11-18
2022-03-31-$3.14M
10-Q · filed 2023-05-11
-$2.68M
derived: sum of 2 quarters · filed 2024-11-18
-$1.64M
derived: sum of 3 quarters · filed 2024-11-18
-$811.00K
derived: sum of 4 quarters · filed 2024-11-18
2021-12-31$455.00K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18
$1.49M
derived: sum of 2 quarters · filed 2024-11-18
$2.33M
derived: sum of 3 quarters · filed 2024-11-18
-$373.00K
10-K/A · filed 2024-11-18
2021-09-30$1.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
$1.87M
derived: sum of 2 quarters · filed 2022-11-03
-$828.00K
10-Q · filed 2022-11-03
$1.65M
derived: sum of 4 quarters · filed 2023-03-02
2021-06-30$833.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
-$1.87M
10-Q · filed 2022-08-04
$608.00K
derived: sum of 3 quarters · filed 2023-03-02
$928.00K
derived: sum of 4 quarters · filed 2023-03-02
2021-03-31-$2.70M
10-Q · filed 2022-05-05
-$225.00K
derived: sum of 2 quarters · filed 2023-03-02
$95.00K
derived: sum of 3 quarters · filed 2023-03-02
-$1.78M
derived: sum of 4 quarters · filed 2023-03-02
2020-12-31$2.48M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02
$2.79M
derived: sum of 2 quarters · filed 2023-03-02
$919.00K
derived: sum of 3 quarters · filed 2023-03-02
-$1.15M
10-K · filed 2023-03-02
2020-09-30$320.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
-$1.56M
derived: sum of 2 quarters · filed 2021-11-04
-$3.62M
10-Q · filed 2021-11-04
-$1.80M
derived: sum of 4 quarters · filed 2022-03-08
2020-06-30-$1.88M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
-$3.94M
10-Q · filed 2021-08-05
-$2.12M
derived: sum of 3 quarters · filed 2022-03-08
$589.00K
derived: sum of 4 quarters · filed 2022-03-08
2020-03-31-$2.06M
10-Q · filed 2021-05-10
-$242.00K
derived: sum of 2 quarters · filed 2022-03-08
$2.46M
derived: sum of 3 quarters · filed 2022-03-08
$4.17M
derived: sum of 4 quarters · filed 2022-03-08
2019-12-31$1.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08
$4.53M
derived: sum of 2 quarters · filed 2022-03-08
$6.23M
derived: sum of 3 quarters · filed 2022-03-08
$5.13M
10-K · filed 2022-03-08
2019-09-30$2.71M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$4.41M
derived: sum of 2 quarters · filed 2020-11-05
$3.30M
10-Q · filed 2020-11-05
$6.28M
derived: sum of 4 quarters · filed 2021-03-18
2019-06-30$1.70M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
$595.00K
10-Q · filed 2020-08-10
$3.58M
derived: sum of 3 quarters · filed 2021-03-18
$4.79M
derived: sum of 4 quarters · filed 2021-03-18
2019-03-31-$1.10M
10-Q · filed 2020-05-07
$1.88M
derived: sum of 2 quarters · filed 2021-03-18
$3.09M
derived: sum of 3 quarters · filed 2021-03-18
$3.28M
derived: sum of 4 quarters · filed 2021-03-18
2018-12-31$2.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18
$4.20M
derived: sum of 2 quarters · filed 2021-03-18
$4.38M
derived: sum of 3 quarters · filed 2021-03-18
$4.17M
10-K · filed 2021-03-18
2018-09-30$1.22M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06
$1.40M
derived: sum of 2 quarters · filed 2019-11-06
$1.19M
10-Q · filed 2019-11-06
$2.37M
derived: sum of 4 quarters · filed 2020-02-24
2018-06-30$185.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06
-$32.00K
10-Q · filed 2019-08-06
$1.15M
derived: sum of 3 quarters · filed 2020-02-24
$1.71M
derived: sum of 4 quarters · filed 2020-02-24
2018-03-31-$217.00K
10-Q · filed 2019-05-07
$963.00K
derived: sum of 2 quarters · filed 2020-02-24
$1.52M
derived: sum of 3 quarters · filed 2020-02-24
$1.54M
derived: sum of 4 quarters · filed 2020-02-24
2017-12-31$1.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24
$1.74M
derived: sum of 2 quarters · filed 2020-02-24
$1.75M
derived: sum of 3 quarters · filed 2020-02-24
$1.67M
10-K · filed 2020-02-24
2017-09-30$559.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
$573.00K
derived: sum of 2 quarters · filed 2018-11-08
$486.00K
10-Q · filed 2018-11-08
$1.01M
derived: sum of 4 quarters · filed 2019-03-07
2017-06-30$14.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09
-$73.00K
10-Q · filed 2018-08-09
$447.00K
derived: sum of 3 quarters · filed 2019-03-07
$582.00K
derived: sum of 4 quarters · filed 2019-03-07
2017-03-31-$87.00K
10-Q · filed 2018-05-08
$433.00K
derived: sum of 2 quarters · filed 2019-03-07
$568.00K
derived: sum of 3 quarters · filed 2019-03-07
$1.27M
derived: sum of 4 quarters · filed 2019-03-07
2016-12-31$520.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07
$655.00K
derived: sum of 2 quarters · filed 2019-03-07
$1.35M
derived: sum of 3 quarters · filed 2019-03-07
$1.83M
10-K · filed 2019-03-07
2016-09-30$135.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
$834.00K
derived: sum of 2 quarters · filed 2017-11-07
$1.31M
10-Q · filed 2017-11-07
$1.81M
derived: sum of 4 quarters · filed 2018-03-13
2016-06-30$699.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09
$1.17M
10-Q · filed 2017-08-09
$1.68M
derived: sum of 3 quarters · filed 2018-03-13
$2.27M
derived: sum of 4 quarters · filed 2018-03-13
2016-03-31$475.00K
10-Q · filed 2017-05-09
$976.00K
derived: sum of 2 quarters · filed 2018-03-13
$1.57M
derived: sum of 3 quarters · filed 2018-03-13
$1.67M
derived: sum of 4 quarters · filed 2018-03-13
2015-12-31$501.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13
$1.10M
derived: sum of 2 quarters · filed 2018-03-13
$1.19M
derived: sum of 3 quarters · filed 2018-03-13
$1.12M
10-K · filed 2018-03-13
2015-09-30$599.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09
$692.00K
derived: sum of 2 quarters · filed 2016-11-09
$618.00K
10-Q · filed 2016-11-09
2015-06-30$93.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09
$19.00K
10-Q · filed 2016-08-09
2015-03-31-$74.00K
10-Q · filed 2016-05-19
2014-12-31$303.00K
10-K · filed 2017-03-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Alkermes plc. (ALKS)$6.844B132.74
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52
Liquidia Corp (LQDA)United States$6.347B51.23
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
CYTOKINETICS INC (CYTK)United States$9.130B-11.86